Damora Therapeutics, Inc. quarterly report, Q2 FY2026

Business Context and Reporting Period

Company: Damora Therapeutics, Inc. (formerly Galecto, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: A biopharmaceutical company developing therapies for hematological malignancies, specifically myeloproliferative neoplasms (MPNs) driven by mutant calreticulin (mutCALR). The company focuses on a portfolio of three product candidates: DMR-001 (Fc-null antibody), DMR-002 (afucosylated antibody), and DMR-003 (bi-specific T-cell engager).
Recent Corporate Actions: In November 2025, the company completed an asset acquisition of "Pre-Acquisition Damora" and a concurrent PIPE transaction. In February 2026, it completed a public offering and converted significant Series C Preferred Stock to Common Stock. In July 2026, the company redomesticated from Delaware to the Cayman Islands.

Key Financial Metrics

Metric (in thousands) Six Months Ended June 30, 2026 Six Months Ended June 30, 2025 Three Months Ended June 30, 2026
Revenue $0 $0 $0
Net Loss $(58,957) $(5,970) $(31,174)
Operating Expenses $65,805 $6,020 $34,994
Research & Development (R&D) $49,317 $2,143 $25,540
General & Administrative (G&A) $16,488 $3,877 $9,454
Cash and Cash Equivalents (End of Period) $540,515 $10,211 $540,515
Net Cash Used in Operating Activities $(42,465) $(4,676) N/A
Net Cash Provided by Financing Activities $325,426 $0 N/A
Accumulated Deficit $(546,320) $(283,494) $(546,320)

Material Changes vs. Prior Period

  • Expense Surge: Total operating expenses increased by 993% to $65.8 million for the six months ended June 30, 2026, compared to $6.0 million in the prior year period. This is primarily due to the integration of the Pre-Acquisition Damora assets and accelerated development activities.
  • R&D Drivers: R&D expenses rose to $49.3 million, driven by $17.8 million in reimbursable costs under the Paragon Option Agreement, $9.5 million in amortized costs for the Paramora warrant obligation, and $18.8 million in Chemistry, Manufacturing, and Control (CMC) activities.
  • Liquidity Position: Cash and cash equivalents increased significantly from $257.6 million at year-end 2025 to $540.5 million at June 30, 2026. This increase was fueled by a February 2026 underwritten public offering (net proceeds ~$295.5 million) and an At-the-Market (ATM) offering (net proceeds ~$29.3 million).
  • Capital Structure: Significant conversions occurred, including the automatic conversion of 42,005 shares of Series C Preferred Stock into 42,005,000 shares of Common Stock following stockholder approval in February 2026.

Guidance, Outlook, and Risks

  • Development Timeline: The company has initiated the Phase 1/1b clinical trial for DMR-001. It plans to submit regulatory filings for DMR-002 in the second half of 2026 and for DMR-003 in 2027. Proof-of-concept readouts for DMR-001 are expected beginning mid-2027.
  • Liquidity Outlook: Management believes existing cash resources of $540.5 million are sufficient to fund operations into the second half of 2029. However, the company expects to continue incurring losses and will require additional capital to complete development and commercialization.
  • Key Risks:
    • Development Risk: No products have been approved for commercial sale; success depends on clinical trial outcomes and regulatory approvals.
    • Third-Party Reliance: Significant reliance on Paragon Therapeutics for research and development under the Paragon Option Agreement, including potential milestone payments up to $22.0 million per product.
    • Regulatory/Geopolitical: Risks associated with the BIOSECURE Act regarding reliance on Chinese contract manufacturing organizations (e.g., WuXi Biologics) and potential tariffs on imported pharmaceuticals.
    • Intellectual Property: The company does not currently own issued patents for its product candidates; rights are held by Paragon and subject to licensing.

Investor Verification Checklist

  • Capital Runway: Verify the accuracy of the "second half of 2029" liquidity projection given the high burn rate ($42.5 million operating cash outflow in six months).
  • Paragon Agreement Terms: Review the specific milestones and payment triggers under the Paragon Option Agreement, particularly the $22.0 million potential liability per product.
  • Manufacturing Supply Chain: Assess the impact of the BIOSECURE Act and potential tariffs on the company's reliance on WuXi Biologics (Hong Kong) for clinical trial materials.
  • Patent Status: Confirm the timeline for transferring patent prosecution control from Paragon to Damora and the status of pending applications for DMR-001, DMR-002, and DMR-003.
  • Stock Dilution: Monitor the remaining capacity under the $150 million ATM facility and the conversion terms of the remaining Series B and Series C Preferred Stock.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.